For the past two years, Cure SMA’s Summit of Strength program has brought together thousands of SMA community members for the opportunity to network and learn about the latest advances in treatment, care, advocacy, and support. Considering event cancellations across the country due to the ongoing pandemic, Cure SMA is now offer these resources through […]
Cure SMA Announces Summit of Strength Virtual Webinar Series Read More »
Dear Members of the SMA Community, In light of the COVID-19 pandemic and the burden it has placed on our healthcare system, Biogen is working with health systems, institutions, physicians, patients and their families to navigate potential SPINRAZA® (nusinersen) dosing delays related to COVID-19. The health and safety of patients is our primary concern, and
Scholar Rock recently reported financial results for the first quarter ending March 31, 2020, highlighting progress and upcoming milestones for its pipeline programs—include the SRK-015 program for spinal muscular atrophy (SMA). Scholar Rock plans to report interim efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) results in the fourth quarter of 2020 for patients across the
Update from Scholar Rock on TOPAZ Phase 2 Clinical Trial of SRK-015 in Patients with SMA Read More »
Genentech, a member of the Roche Group, today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1-7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for 5 seconds by month
Navigating the recent global health crisis, Coronavirus (COVID-19), has reinforced for us the importance of understanding what the SMA community is thinking, feeling, and experiencing. This allows us to more effectively support those impacted by SMA, both with the everyday needs you have and during greater public health challenges. Without this knowledge, we cannot advocate
Annual Cure SMA Community Update Survey Ready for Your Input Read More »
Despite the new reality of quarantines, remote working, and social distancing, Cure SMA would like you to know that our work for the SMA community continues. Cure SMA remains vigilant in monitoring and responding to the needs of the SMA community, as your health, safety, and well-being is our top priority. We are launching a
Cure SMA Launches New COVID-19 Support Package Read More »
Cure SMA realizes that quarantining is essential for individuals and families who live with SMA, many of whom are experiencing hardships due to the COVID-19 pandemic. In response, we are pleased to launch a new program designed to help alleviate some of the financial burden for those in the SMA community who are affected in
COVID-19 Assistance Program Available to SMA Community Read More »
This article is the last in a series of Cure SMA grant announcements that have been shared throughout the past months. Cure SMA has awarded a $190,000 research grant to Stephen Meriney, Ph.D., at the University of Pittsburgh for his project titled, “A novel treatment targeting persistent neuromuscular dysfunction in a mild mouse model of
Cure SMA has been closely monitoring news and reports of the Coronavirus (COVID-19) outbreak, allowing us to make decisions about local events and offer new resources that support the SMA community. The current status of the pandemic and associated governmental regulations, restrictions, and advisories, as well as the need to protect those with SMA who
Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA community, healthcare providers, and our employees and partners. We know that life with a rare genetic disease can bring significant challenges,
